Klivira
Request demo

Optimizing Emgality Prior Authorization for Gastroenterology Practices

Managing **Emgality prior authorization for gastroenterology** practices demands a robust and efficient system to navigate payer requirements and minimize administrative delays. Klivira provides the automation needed to streamline this high-volume process.

Gastroenterology practices face a significant prior authorization burden, not only for GI-specific biologics and procedures but also for specialty medications prescribed for comorbidities. While Emgality (galcanezumab) is primarily indicated for migraine prevention, its high PA volume across commercial, Medicare Advantage, and Medicaid managed care plans means GI clinics within integrated health systems or those managing complex patients may encounter its authorization requirements, adding to an already complex operational landscape.

The Operational Intersection of Emgality and GI Prior Authorization

While Emgality is a CGRP inhibitor for migraine, gastroenterology practices often operate within health systems or manage patients with complex comorbidities. This means the administrative task of securing Emgality prior authorization can fall to the same teams managing PAs for IBD biologics, advanced imaging, or endoscopic procedures. The operational challenges—such as step therapy compliance and re-authorization cycles—are consistent across specialty medications.

Navigating High-Volume Prior Authorizations in Gastroenterology

Gastroenterology is characterized by a high volume of prior authorizations across several categories. This includes crucial IBD biologics like Humira, Stelara, Skyrizi, and Entyvio, as well as complex procedures and specialty IBD drugs. The existing infrastructure for managing these PAs must also accommodate other high-PA-burden medications like Emgality, ensuring efficient processing regardless of the specific indication.

Key Documentation Considerations for Specialty Drugs in GI Settings

  • Accurate diagnosis confirmation, often requiring specific diagnostic criteria relevant to the condition being treated.
  • Comprehensive patient history, including prior therapy trials and documented failures to satisfy step therapy requirements.
  • Relevant screening results (e.g., TB/Hepatitis for biologics, or specific neurological workup for CGRP inhibitors).
  • Disease severity assessments, such as Mayo score for UC or CDAI for Crohn's, or appropriate severity scales for other conditions.
  • Clear justification for non-formulary or off-label use, if applicable, aligning with ACG, AGA, or AASLD guidelines.

Common Prior Authorization Denials Affecting Specialty Medications

Denials for specialty drugs, including Emgality or GI biologics, frequently stem from similar issues. These include non-compliance with step therapy protocols, insufficient documentation of disease severity or prior treatment failures, and missing pre-screening results. Addressing these common pitfalls is critical for improving PA approval rates across the board and reducing the administrative burden on GI practices.

Klivira's Platform for Comprehensive Prior Authorization Automation

Klivira's platform provides a robust solution for the diverse prior authorization needs of gastroenterology practices. By integrating with leading EMRs via SMART on FHIR, Klivira automates data extraction and submission, streamlining the process for both GI-specific treatments and other high-volume specialty drugs like Emgality, ensuring compliance with payer-specific guidelines and reducing manual effort.

Frequently asked questions

Why would a gastroenterology practice need to process Emgality prior authorizations?

While Emgality is primarily for migraine, GI practices, especially those within larger health systems or managing patients with complex comorbidities, may prescribe it. The administrative burden of processing Emgality PAs then falls to the same revenue cycle teams accustomed to managing prior authorizations for GI-specific biologics and procedures.

How does Klivira handle step therapy requirements for specialty drugs like Emgality or IBD biologics?

Klivira's platform incorporates payer-specific policy logic, including ACG/AGA-guideline-aware step therapy sequencing for IBD biologics. For any specialty drug, Klivira automates the identification and documentation of prior therapy trials and failures, ensuring submissions meet payer requirements and reducing denial rates.

What EMR integration capabilities does Klivira offer for GI practices?

Klivira integrates with major EMR systems using industry standards like SMART on FHIR. This allows for seamless extraction of patient data, medication histories, diagnostic results, and clinical notes directly from the EMR, populating PA forms and supporting documentation for efficient submission.

Can Klivira assist with the periodic re-authorization burden common in gastroenterology?

Yes, Klivira specifically addresses the chronic-treatment ongoing PA burden common in gastroenterology for IBD biologics, and similarly for other long-term specialty medications. The platform automates tracking and initiation of re-authorization cycles, prompting for necessary updated documentation of disease response and compliance.

How does Klivira help reduce denials for specialty drug PAs in a GI setting?

Klivira reduces denials by ensuring submissions are complete, accurate, and compliant with payer-specific medical necessity criteria and step therapy protocols. Automated checks for missing documentation (e.g., screening results, disease severity scores) and real-time alerts help prevent common denial reasons before submission.

Related coverage

Other emgality prior authorization by payer

Other emgality prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo